E M H Swiss Medical Publishers Ltd

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Drilon
    Drilon
  3. Koche
    Koche
  4. Rosenberg
    Rosenberg
  5. Sherman
    Sherman
  6. Yang
    Yang
  7. Modi
    Modi
  8. Morris
    Morris
  9. Cercek Hanjis
    Cercek Hanjis
  10. Landau
    Landau

Groups

  1. Department of Medicine (26)
  2. Solid Tumor Oncology Division (14)
  3. Center for Hematologic Malignancies (13)
  4. Center for Molecular Imaging and Biotechnology (13)
  5. GSK Faculty (13)
  6. Executive Committee, Center for Hematologic Malignancies (12)
  7. Hematologic Malignancies, Division of (12)
  8. Adult Leukemia (11)
  9. Human Oncology and Pathogenesis Program (11)
  10. Genitourinary Oncology Service (5)
Search Within
Formats
  1. Meeting Abstract (27)
  2. Journal Article (2)
Groups
  1. Department of Medicine (26)
  2. Solid Tumor Oncology Division (14)
  3. Center for Hematologic Malignancies (13)
  4. Center for Molecular Imaging and Biotechnology (13)
  5. GSK Faculty (13)
  6. Executive Committee, Center for Hematologic Malignancies (12)

More Groups

People
  1. Ross Levine (11)
  2. Alexander Drilon (4)
  3. Eric Sherman (3)
  4. Jonathan Rosenberg (3)
  5. Li Yang (3)
  6. Richard Koche (3)

More People

Years
  1. 2023 (4)
  2. 2022 (7)
  3. 2021 (5)
  4. 2020 (8)
  5. 2019 (3)
  6. 2018 (1)

More Years

Publications
  1. Swiss Medical Weekly (29)

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Myocardial energetics and myocardial blood flow across the spectrum of light chain amyloidosis
    Meeting Abstract

    Benz, D. C.; Clerc, O.; Ge, Y.; Neri, J. C.; Taylor, A.; Kijewski, M. F.; Bianchi, G.; Yee, A. J.; Sanchorawala, V.; Ruberg, F. L.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • Updated overall efficacy and safety of selpercatinib in patients with RET fusion-positive non-small-cell lung cancer (NSCLC): LIBRETTO-001 study
    Meeting Abstract

    Besse, B.; Drillon, A. E.; Solomon, B. J.; Subbiah, V.; Tan, D. S. W.; Park, K.; De Braud, F. G.; Alonso, G.; Wolf, J.; Soldatenkova, V.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Scherz, A.; Felip, E.; Garassino, M.; Sakai, H.; Le, X.; Veillon, R.; Smit, E.; MazieĢ€res, J.; Cortot, A.; Raskin, J.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301
    Meeting Abstract

    Gurney, H.; Mamtani, R.; Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update
    Meeting Abstract

    Sherman, E.; Wirth, L.; Shah, M.; Cabanillas, M.; Robinson, B.; Italiano, A.; Laskin, J.; Subbiah, V.; Drilon, A.; Wright, J.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Stivala, S.; Brkic, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Flaig, T. W.; Friedlander, T. W.; Milowsky, M. I.; Srinivas, S.; Petrylak, D. P.; Merchan, J. R.; Bilen, M. A.; Carret, A. S.; Yuan, N.; more...
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study
    Meeting Abstract

    Krop, I.; Manich, C. S.; Yamashita, T.; Park, Y. H.; Kim, S. B. K.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Meeting Abstract

    Zaman, K.; Modi, S.; Ohtan, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a potent therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save

    • E M H Swiss Medical Publishers Ltd – authorized name for: